Across TCGA pan-cancer cohorts, SLC22A24 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC22A24 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC22A24 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC22A24 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and PRAD are the cancer types where SLC22A24 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.197	0.720	.004	18	view →
UCEC	DFS	Median	All	1.000	0.891	.017	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
ESCA	OS	Median	II,III,IV	0.345	0.686	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SLC22A24 tumor-vs-normal RNA expression · all SLC22A24 data types